August 11, 2022 | Daily JAM, RUN, SGMO, Volatility |
Yesterday’s bounce on the better-than-expected July CPI inflation numbers–the annual rate dropped to 8.5% from 9.1% in June while economists surveyed by Bloomberg were expecting a drop to an 8.7% rate–looks to be fading today, August 11, but I’m going to squeeze in two more sells, Sangamo Therapeutics (SGMO) and Sunrun (RUN) for tomorrow to take advantage of this Bear Market rally. Both sells are out of my Volatility Portfolio. The high potential upside of these two picks has driven them to big gains in the Bear Market rally that began in July. That same volatility, on the downside, makes them stocks I don’t want to hold in any return of the Bear Market.
November 5, 2021 | Daily JAM, Short Term |
The dominoes keep tumbling and I think we’re now set up for one of those extremely volatile market melt ups through early January. Why do I believe that? And what’s a melt up look like? Glad you asked.
November 4, 2021 | Daily JAM, SGMO, Volatility |
Shares of Sangamo Therapeutics (SGMO) closed 19.15% higher today, November 4, on good news from multiple clinical trials at the gene therapy company.
January 10, 2021 | Daily JAM |
The big JPMorgan Chase healthcare conference that began today, January 10, and that runs for the rest of this week, will keep biotech stock prices moving up even as valuations in the sector look increasingly stretched.
December 14, 2020 | Daily JAM, Short Term |
I see all the signs of a market that’s moved beyond enthusiasm to excess. This stage in a market is called many things. A market melt. Forming a top. You get the idea. We won’t, of course, know if the current levels constitute a top until we get a sustained downturn. And waiting for that confirming downturn can take a while and be very painful if you’ve tried to time the turn with shorts or Put Options and turn out to have been early. The topping process can go on for a while.
December 10, 2020 | Daily JAM, Stock Alerts, Volatility |
Shares of gene therapy player Sangamo Therapeutics (SGMO) soared 52.98% in the regular session today, December 10, and tacked on another 3.77% in after-hours trading. I always try to understand a huge one-day move like that–and frankly I frequently fail. Here’s my take on Sangamo’s big move on Thursday.
July 9, 2019 | Daily JAM, SGMO, Stock Alerts, Volatility |
On July 5 Sangamo Therapeutics (SGMO) and partner Pfizer (PFE) announced update results of a Phase 1/2 study of Sangamo's SB-525 gene therapy for severe hemophilia A. The companies also announced that the U.S. Food & Drug Administration had granted regenerative...
April 2, 2019 | Daily JAM, SGMO, Stock Alerts |
Two big pieces of positive news popped shares of Sangamo Therapeutics (SGMO) today by 28.96% at the close. First, Sangamo announced interim data from its Hemophilia A program with Pfizer (PFE). The SB-525 gene therapy Phase 1/2 study in eight patients showed...
December 11, 2018 | Daily JAM, SGMO |
As an investor in Sangamo (SGMO) the very slow and cautious pace of regulatory action at the U.S. Food & Drug Administration is frustrating. The FDA has only slowly allowed the company to expand the number of patients enrolled in the the safety trials for its new...
December 3, 2018 | ALV, AMZN, CAT, CTRP, Daily JAM, DE, FCX, FQVLF, NVDA, SGMO, Volatility, ZNH |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
November 27, 2018 | Daily JAM, Short Term, Special Reports, WST |
Two robins don't make a spring. And two bounces--even when one of them is a really big bounce like that of Wednesday November 28--don't make a January Effect Rally in  small company stocks. But it sure looks to me like the sector is setting up for a typical January...
October 9, 2018 | Daily JAM, SGMO, Stock Alerts |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
